Kearny Venture Partners

Company	Description	Status



	Developing and commercializing Invisalign, the world’s leading invisible orthodontic product	Public [NASDAQ: ALGN]



	Developing catheter-based devices for the prevention of stroke	Acquired by eV3 [NASDAQ: EVVV]



	Developing and commercializing new indications for existing medicines	Acquired by Galencia



	Developing tools to restore spine function and preserve healthy tissue.	Private



	Developing and commercializing medicines for cardiovascular diseases	Acquired by Actelion



	Developing implantable devices for the treatment of hypertension	Private



	Developing minimally invasive therapies for patients with pulmonary diseases	Private



	Developing devices to enable percutaneous repair of heart valves	Private



	Developing and commercializing the Crystalens technology, an accommodating intraocular lens	Acquired by Bausch & Lomb



	Developing and commercializing devices for the treatment of peripheral arterial disease	Acquired by eV3 [NASDAQ: EVVV]



	Developing technology to enable controlled movement of catheters in three-dimensional spaces within the body	Public [NASDAQ: HNSN]



	Developing and commercializing minimally invasive devices for volumetric excision of tissue for diagnosis and therapy	Private



	Developing protein therapeutics for cardiovascular disease and pain	Private



	Developing and commercializing catheter-based solutions for treatment of chronic total occlusions in blood vessels	Acquired by J&J [NYSE: JNJ]



	Developing new therapies for endocrine, metabolic and cardiovascular indications	Private



	Developing novel classes of antibiotics using structure based design	Private



	Developing new products for the treatment of pain	Private



	Developing minimally invasive solutions for the treatment of obesity	Private



	Developing replacement discs for diseases of the spine	Private



	Developing minimally invasive surgical procedures for diseases of the spine	Public [NASDAQ: TSON]



	Developing endovascular devices for treatment of aortic aneurysmal disease	Acquired by Boston Scientific [NYSE: BSX]



	Developing endovascular devices for treatment of aortic aneurysmal disease. Assets repurchased from Boston Scientific.	Private



	Developing small molecule medicines for respiratory disease, bacterial infections, and gastrointestinal disorders	Public [NASDAQ: THRX]



	Developing next generation radiotherapy devices	Private



	Developing and commercializing cutting balloon technology for the treatment of coronary artery disease	Acquired by Guidant [NASDAQ: BSX]